Watch SGRY. Know when insiders buy.
One email the day a filing lands. Free.
SGRY
Surgery Partners, Inc.
14.60
+0.20 +1.39%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
44
WATCH · shorts 44
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.9BP/E —DIV YIELD —FCF YIELD 9.81%REV TTM —NET INCOME −$88.6MNET DEBT $3.5B52W 11.49 – 22.94SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | $102.1M | −$15M | — | -0.12 | $59.3M | $21.8M | $37.5M | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | $65.8M | −$35.9M | — | -0.28 | $11.7M | $16M | −$4.3M | May 5 |
| Q4 2025 · Dec 31derived | — | — | — | $110.2M | −$15M | — | -0.11 | $103.4M | $12.8M | $90.6M | Mar 2 |
| Q3 2025 · Sep 30 | — | — | — | $105.7M | −$22.7M | — | -0.18 | $83.6M | $19.8M | $63.8M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | $111.7M | −$2.5M | — | -0.02 | $81.3M | $23.4M | $57.9M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | $61.9M | −$37.7M | — | -0.30 | $6M | $22.7M | −$16.7M | May 5 |
| Q4 2024 · Dec 31derived | — | — | — | $127.1M | −$108.5M | — | -0.86 | $111.4M | $22.3M | $89.1M | Mar 2 |
| Q3 2024 · Sep 30 | — | — | — | $60.9M | −$31.7M | — | -0.25 | $65.2M | $20.2M | $45M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | $84.8M | −$15.5M | — | -0.12 | $82.8M | $26.9M | $55.9M | Aug 5 |
| Q1 2024 · Mar 31 | — | — | — | $76M | −$12.4M | — | -0.10 | $40.7M | $21M | $19.7M | May 12 |
| Q4 2023 · Dec 31derived | — | — | — | $101.4M | −$1M | — | 0.00 | $62.6M | $19.8M | $42.8M | Mar 2 |
| Q3 2023 · Sep 30 | — | — | — | $82.6M | −$4.9M | — | -0.04 | $104.6M | $18.9M | $85.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | $389.5M | −$77.9M | — | -0.61 | $274.3M | $78.7M | $195.6M | — | — |
| FY2024 · to Dec 31 | — | — | $348.8M | −$168.1M | — | -1.33 | $300.1M | $90.4M | $209.7M | — | — |
| FY2023 · to Dec 31 | — | — | $328M | −$11.9M | — | -0.09 | $293.8M | $88.8M | $205M | — | — |
| FY2022 · to Dec 31 | — | — | $345.2M | −$54.6M | — | -0.59 | $158.8M | $80.6M | $78.2M | — | — |
| FY2021 · to Dec 31 | — | — | $302.2M | −$70.9M | — | -1.12 | $87.1M | $57.6M | $29.5M | — | — |
| FY2020 · to Dec 31 | — | — | $183M | −$116.1M | — | -3.19 | $246.9M | $42.9M | $204M | $0 | — |
Every number comes from Surgery Partners, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.